It has been 20 years since the FDA approved a new sunscreen filter. However, a recent study evaluating curcumin could change that.
There are an increasing number of novel immunotherapies available for patients with skin cancer, however, their numerous adverse events must be addressed.
Part 1 of Dermatology Times®’ coverage of a strategic look at superficial radiation therapy (SRT) presented at the recent Music City SCALE Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting in Nashville, Tennessee, showcases this therapy’s efficacy in treating keratinocytic skin cancers.
Curcumin has a long history as an effective treatment for everything from chronic pain to skin infections. Nanoparticle encapsulation shows promise in meeting that challenge and opening the way for a safe, effective adjuvant to sunscreen.
A phase 2 clinical trial on remetinostat for the treatment of BCC in adult patients has been published in the Clinical Cancer Research journal and shows promising results.
In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.
In this exclusive video interview, Christopher Bunick, MD, PhD, gives Dermatology Times an update on benzene contamination being detected in various sunscreens and after-sun care products, as well as a recent recall by Johnson & Johnson.
Christopher Bunick, MD, PhD, provides an update on benzene contamination in sunscreen, including a recent recall from Johnson & Johnson.
The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.